Literature DB >> 30689991

Earliest Evidence of Preclinical Diabetic Retinopathy Revealed Using Optical Coherence Tomography Angiography Perfused Capillary Density.

Richard B Rosen1, Jorge S Andrade Romo2, Brian D Krawitz3, Shelley Mo3, Amani A Fawzi4, Rachel E Linderman5, Joseph Carroll6, Alexander Pinhas7, Toco Y P Chui3.   

Abstract

PURPOSE: To compare perfused capillary density (PCD) in diabetic patients and healthy controls using optical coherence tomography angiography (OCTA).
METHODS: Forty controls, 36 diabetic subjects without clinical retinopathy (NoDR), 38 with nonproliferative retinopathy (NPDR), and 38 with proliferative retinopathy (PDR) were imaged using spectral-domain optical coherence tomography. A 3 × 3-mm full-thickness parafoveal OCTA scan was obtained from each participant. Following manual delineation of the foveal avascular zone (FAZ), FAZ area, perimeter, and acircularity index were determined. Seven consecutive equidistant 200-μm-wide annular segments were drawn at increasing eccentricities from the FAZ margin. Annular PCD (%) was defined as perfused capillary area divided by the corresponding annulus area after subtraction of noncapillary blood vessel areas. Nonparametric Kruskal-Wallis testing with Bonferroni correction was performed in pairwise comparisons of group PCD values.
RESULTS: The NoDR group demonstrated consistently higher PCD compared to the control group in all 7 annuli, reaching statistical significance (36.6% ± 3.30% vs 33.6% ± 3.98%, P = .034) at the innermost annulus (FAZ margin to 200 μm out). The NPDR and PDR groups demonstrated progressively decreasing PCD. Differences in FAZ metrics between the NoDR and control groups did not reach statistical significance.
CONCLUSIONS: Relative to healthy controls, increased PCD values in the NoDR group likely represent an autoregulatory response to increased metabolic demand, while the decrease in PCD that follows in NPDR and PDR results largely from an incremental loss of capillary segments. These findings, consistent with previous studies, demonstrate the potential of OCTA as a clinical tool for earlier objective detection of preclinical diabetic retinopathy. NOTE: Publication of this article is sponsored by the American Ophthalmological Society.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2019        PMID: 30689991      PMCID: PMC6612596          DOI: 10.1016/j.ajo.2019.01.012

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  74 in total

1.  The 25-year incidence of visual impairment in type 1 diabetes mellitus the wisconsin epidemiologic study of diabetic retinopathy.

Authors:  Ronald Klein; Kristine E Lee; Ronald E Gangnon; Barbara E K Klein
Journal:  Ophthalmology       Date:  2009-10-31       Impact factor: 12.079

2.  Defective myogenic response to posture change in retinal vessels of well-controlled type 1 diabetic patients with no retinopathy.

Authors:  Mara Lorenzi; Gilbert T Feke; Linda Pitler; Fatmire Berisha; Julia Kolodjaschna; J Wallace McMeel
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-30       Impact factor: 4.799

3.  Glucose and insulin exert additive ocular and renal vasodilator effects on healthy humans.

Authors:  A Luksch; K Polak; B Matulla; S Dallinger; S Kapiotis; G Rainer; M Wolzt; L Schmetterer
Journal:  Diabetologia       Date:  2001-01       Impact factor: 10.122

Review 4.  Anti-inflammatory therapy for diabetic retinopathy.

Authors:  Wenbo Zhang; Hua Liu; Modesto Rojas; Robert W Caldwell; Ruth B Caldwell
Journal:  Immunotherapy       Date:  2011-05       Impact factor: 4.196

5.  Increased retinal blood flow velocity in patients with early diabetes mellitus.

Authors:  Zvia Burgansky-Eliash; Adiel Barak; Hila Barash; Darin A Nelson; Orly Pupko; Anat Lowenstein; Amiram Grinvald; Ardon Rubinstein
Journal:  Retina       Date:  2012-01       Impact factor: 4.256

6.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.

Authors:  N Sarwar; P Gao; S R Kondapally Seshasai; R Gobin; S Kaptoge; E Di Angelantonio; E Ingelsson; D A Lawlor; E Selvin; M Stampfer; C D A Stehouwer; S Lewington; L Pennells; A Thompson; N Sattar; I R White; K K Ray; J Danesh
Journal:  Lancet       Date:  2010-06-26       Impact factor: 202.731

7.  Are individuals with diabetes seeing better?: a long-term epidemiological perspective.

Authors:  Ronald Klein; Barbara E K Klein
Journal:  Diabetes       Date:  2010-08       Impact factor: 9.461

8.  A central role for inflammation in the pathogenesis of diabetic retinopathy.

Authors:  Antonia M Joussen; Vassiliki Poulaki; Minh Ly Le; Kan Koizumi; Christina Esser; Hanna Janicki; Ulrich Schraermeyer; Norbert Kociok; Sascha Fauser; Bernd Kirchhof; Timothy S Kern; Anthony P Adamis
Journal:  FASEB J       Date:  2004-07-01       Impact factor: 5.191

9.  Reduced retinal blood flow velocity in diabetic retinopathy.

Authors:  Zvia Burgansky-Eliash; Darin A Nelson; Orly Pupko Bar-Tal; Anat Lowenstein; Amiram Grinvald; Adiel Barak
Journal:  Retina       Date:  2010-05       Impact factor: 4.256

10.  Dynamic changes in the microcirculation of diabetics as related to diabetic microangiopathy.

Authors:  E M Kohner
Journal:  Acta Med Scand Suppl       Date:  1975
View more
  34 in total

1.  [Optical coherence tomography angiography (OCT-A) : Overview of the technique and the possible clinical and scientific applications].

Authors:  Maged Alnawaiseh; Martin Dominik Leclaire; Nicole Eter
Journal:  Ophthalmologe       Date:  2021-04-21       Impact factor: 1.059

2.  Macula Vessel Density and Foveal Avascular Zone Parameters in Exfoliation Glaucoma Compared to Primary Open-Angle Glaucoma.

Authors:  Shawn Philip; Ahmad Najafi; Apichat Tantraworasin; Toco Y P Chui; Richard B Rosen; Robert Ritch
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-03-01       Impact factor: 4.799

3.  Reconstruction of high-resolution 6×6-mm OCT angiograms using deep learning.

Authors:  Min Gao; Yukun Guo; Tristan T Hormel; Jiande Sun; Thomas S Hwang; Yali Jia
Journal:  Biomed Opt Express       Date:  2020-06-08       Impact factor: 3.732

4.  Prevalence and Severity of Artifacts in Optical Coherence Tomographic Angiograms.

Authors:  Ian C Holmen; Sri Meghana Konda; Jeong W Pak; Kyle W McDaniel; Barbara Blodi; Kimberly E Stepien; Amitha Domalpally
Journal:  JAMA Ophthalmol       Date:  2020-02-01       Impact factor: 7.389

Review 5.  Perspectives on diabetic retinopathy from advanced retinal vascular imaging.

Authors:  Janice X Ong; Amani A Fawzi
Journal:  Eye (Lond)       Date:  2022-01-05       Impact factor: 3.775

6.  Microvascular retinal changes in pre-clinical diabetic retinopathy as detected by optical coherence tomographic angiography.

Authors:  Jing Yan Yang; Qian Wang; Yan Ni Yan; Wen Jia Zhou; Ya Xing Wang; Shou Ling Wu; Ming Xia Yuan; Wen Bin Wei; Jost B Jonas
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-01-02       Impact factor: 3.117

7.  Ocular blood flow as a clinical observation: Value, limitations and data analysis.

Authors:  Alon Harris; Giovanna Guidoboni; Brent Siesky; Sunu Mathew; Alice C Verticchio Vercellin; Lucas Rowe; Julia Arciero
Journal:  Prog Retin Eye Res       Date:  2020-01-24       Impact factor: 21.198

Review 8.  Quantitative optical coherence tomography angiography: A review.

Authors:  Xincheng Yao; Minhaj N Alam; David Le; Devrim Toslak
Journal:  Exp Biol Med (Maywood)       Date:  2020-01-20

Review 9.  Artificial intelligence in OCT angiography.

Authors:  Tristan T Hormel; Thomas S Hwang; Steven T Bailey; David J Wilson; David Huang; Yali Jia
Journal:  Prog Retin Eye Res       Date:  2021-03-22       Impact factor: 21.198

10.  Foveal Avascular Zone Does Not Correspond to Choroidal Characteristics in Patients with Diabetic Retinopathy: A Single-Center Cross-Sectional Analysis.

Authors:  Patryk Sidorczuk; Barbara Pieklarz; Joanna Konopinska; Emil Saeed; Zofia Mariak; Diana Dmuchowska
Journal:  Diabetes Metab Syndr Obes       Date:  2021-06-28       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.